Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496291 | 0.88 | KDM4E (0.47) | PKMALDH1A1POLBKDRLMNA | |
| SCHEMBL1496283 | 0.86 | ACLY (0.50) | ALDH1A1POLBKDRLMNATDP1 | |
| SCHEMBL1496282 | 0.84 | KDR (0.64) | POLBKDRHSD17B10LMNAALOX15 | |
| SCHEMBL1496405 | 0.84 | KDR (0.47) | PKMALDH1A1POLBKDRLMNA | |
| SCHEMBL1496358 | 0.83 | KDR (0.59) | POLBKDRHSD17B10LMNAALOX15 | |
| SCHEMBL1496378 | 0.80 | SMN1; SMN2 (0.44) | ALDH1A1POLBKDRLMNAL3MBTL1 | |
| SCHEMBL1496259 | 0.80 | KDR (0.58) | KDRLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL1941030 | 0.80 | PKM (0.57) | PKMALDH1A1POLBKDRHSD17B10 | |
| SCHEMBL4017457 | 0.79 | KDR (0.69) | PKMALDH1A1POLBKDRHSD17B10 | |
| Hydrochloric Acid SCHEMBL3924243 | 0.79 | PKM (0.56) | PKMALDH1A1POLBKDRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | claimed |
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | claimed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | claimed |
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1854787-A1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SQOR, QSOX1, SQLE | PKM 2456/4885ALDH1A1 1108/4885POLB 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.